C Poethko-Müller1, N Buttmann-Schweiger. 1. Abteilung für Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut, General-Pape-Straße 62-66, 12101, Berlin, Deutschland, poethko-muellerc@rki.de.
Abstract
OBJECTIVES: In Germany, vaccination against HPV infection has been recommended for girls aged 12-17 years since 2007. The aim of this paper was to provide an overview of the current status and determinants of HPV vaccination uptake in Germany. METHODS: Analyses included data from 14- to 17-year-old girls (n =1,337) of the German Health Interview and Examination Survey for Children and Adolescents - First Follow-up Survey (KiGGS Wave 1). Standardized telephone interviews included questions for girls on the number of HPV vaccine doses and visits to a gynecologist. Parents were asked about their socioeconomic status (SES) and the girls' participation in the J1 adolescent health check-up. Descriptive analyses of the HPV vaccination status with respect to social, demographic, and health-care utilization factors were performed. Factors associated with vaccination were identified and odds ratios (OR) were estimated by means of logistic regression analysis. RESULTS: The prevalence of vaccination with at least one HPV vaccine dose was 52.6% (95% confidence interval 48.5-56.6). Three-dose HPV vaccination coverage was 39.5% (35.3-43.9). Vaccine uptake increased with age, was higher in girls with middle and low SES compared with high SES, with residence in eastern Germany, in those who had already seen a gynecologist, and who participated in the J1. Multivariable logistic regression revealed a twofold increased chance of being vaccinated for girls with middle SES (OR 1.9) compared with high-SES girls and for those who had yet seen a gynecologist (OR 2.1). CONCLUSIONS: School-based vaccination programs and multi-tier vaccination campaigns have led to high vaccination rates in some European and non-European countries. In Germany, however, such high vaccination rates have not been achieved. To fully realize the potential of HPV vaccinations to reduce HPV-related cancer incidence at the population level, vaccination coverage in Germany must be increased. In absence of school-based vaccination programs, medical doctors should use each visit to check and complete the girl's vaccination status.
OBJECTIVES: In Germany, vaccination against HPV infection has been recommended for girls aged 12-17 years since 2007. The aim of this paper was to provide an overview of the current status and determinants of HPV vaccination uptake in Germany. METHODS: Analyses included data from 14- to 17-year-old girls (n =1,337) of the German Health Interview and Examination Survey for Children and Adolescents - First Follow-up Survey (KiGGS Wave 1). Standardized telephone interviews included questions for girls on the number of HPV vaccine doses and visits to a gynecologist. Parents were asked about their socioeconomic status (SES) and the girls' participation in the J1 adolescent health check-up. Descriptive analyses of the HPV vaccination status with respect to social, demographic, and health-care utilization factors were performed. Factors associated with vaccination were identified and odds ratios (OR) were estimated by means of logistic regression analysis. RESULTS: The prevalence of vaccination with at least one HPV vaccine dose was 52.6% (95% confidence interval 48.5-56.6). Three-dose HPV vaccination coverage was 39.5% (35.3-43.9). Vaccine uptake increased with age, was higher in girls with middle and low SES compared with high SES, with residence in eastern Germany, in those who had already seen a gynecologist, and who participated in the J1. Multivariable logistic regression revealed a twofold increased chance of being vaccinated for girls with middle SES (OR 1.9) compared with high-SES girls and for those who had yet seen a gynecologist (OR 2.1). CONCLUSIONS: School-based vaccination programs and multi-tier vaccination campaigns have led to high vaccination rates in some European and non-European countries. In Germany, however, such high vaccination rates have not been achieved. To fully realize the potential of HPV vaccinations to reduce HPV-related cancer incidence at the population level, vaccination coverage in Germany must be increased. In absence of school-based vaccination programs, medical doctors should use each visit to check and complete the girl's vaccination status.
Authors: Ralf B Uken; Oliver Brummer; Carolin von Schubert-Bayer; Thomas Brodegger; Ingo U Teudt Journal: Eur Arch Otorhinolaryngol Date: 2016-03-09 Impact factor: 2.503
Authors: Oliver Damm; Johannes Horn; Rafael T Mikolajczyk; Mirjam E E Kretzschmar; Andreas M Kaufmann; Yvonne Deleré; Bernhard Ultsch; Ole Wichmann; Alexander Krämer; Wolfgang Greiner Journal: Cost Eff Resour Alloc Date: 2017-09-04
Authors: Anna Sternjakob-Marthaler; Barbara Berkó-Göttel; Jürgen Rissland; Jakob Schöpe; Emeline Taurian; Hanna Müller; Gero Weber; Stefan Lohse; Thomas Lamberty; Bernd Holleczek; Harry Stoffel; Gunter Hauptmann; Martin Giesen; Christiane Firk; Alexandra Schanzenbach; Florian Brandt; Heike Hohmann; Quirin Werthner; Dominik Selzer; Thorsten Lehr; Stefan Wagenpfeil; Sigrun Smola Journal: PLoS One Date: 2022-09-02 Impact factor: 3.752
Authors: Maurane Riesen; Garyfallos Konstantinoudis; Ben D Spycher; Christian L Althaus; Phung Lang; Nicola Low; Christoph Hatz; Mirjam Maeusezahl; Anne Spaar; Marc Bühlmann Journal: BMJ Open Date: 2018-05-17 Impact factor: 2.692